Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

2.

Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.

Malloy RJ, Kanaan AO, Silva MA, Donovan JL.

Clin Ther. 2013 Oct;35(10):1490-1500.e7. doi: 10.1016/j.clinthera.2013.09.004.

PMID:
24139421
3.

Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke.

Warlow C.

Stroke. 2002 Aug;33(8):2137-8. No abstract available.

4.

Aspirin therapy should be first-line treatment in secondary prevention of stroke--against.

Diener HC.

Stroke. 2002 Aug;33(8):2138-9. No abstract available.

6.

What's new in stroke? The top 10 studies of 2006-2008. Part I.

Hart RG.

Pol Arch Med Wewn. 2008 Nov;118(11):650-7. Review.

7.

Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.

Simmons BB, Yeo A, Fung K; American Heart Association; American Stroke Association.

Postgrad Med. 2010 Mar;122(2):49-53. doi: 10.3810/pgm.2010.03.2121. Review.

PMID:
20203455
8.

Newer antiplatelet therapies in stroke prevention.

Davis SM, Donnan GA.

Aust Fam Physician. 2001 Feb;30(2):129-34.

PMID:
11280112
9.

[Secondary prevention with clopidogrel after TIA or stroke].

Zuurbier SM, Vermeer SE, Hilkens PH, Algra A, Roos YB.

Ned Tijdschr Geneeskd. 2013;157(25):A5836. Review. Dutch.

PMID:
23777963
10.

[Secondary stroke prevention according to the PRoFESS Study. What are the sequelae for practical therapy?].

Diener C.

MMW Fortschr Med. 2008 May 22;150(21):7. German. No abstract available.

PMID:
18578065
11.

Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs--is antiplatelet monotherapy still reasonable?

Diener HC, Weber R, Weimar C, Röther J.

Int J Clin Pract. 2011 May;65(5):531-5. doi: 10.1111/j.1742-1241.2010.02621.x. Review. No abstract available.

PMID:
21489077
12.

[Recurrence prophylaxis for stroke patients. Which platelet inhibitor combination protects best?].

[No authors listed]

MMW Fortschr Med. 2003 Jul 24;145(29-30):63. German. No abstract available.

PMID:
12958789
13.
14.

[ASS plus dipyridamole or clopidogrel after stroke: what is the best secondary prevention?].

Einecke D.

MMW Fortschr Med. 2008 May 22;150(21):6-7. German. No abstract available.

PMID:
18575244
15.

Update on the use of antiplatelet agents in secondary stroke prevention.

Jamieson DG.

J Natl Med Assoc. 2007 Mar;99(3):306. No abstract available.

16.

Counting the true cost of antiplatelet therapy for stroke prevention.

Morton JA, Newton J, Gray CS.

Age Ageing. 2005 May;34(3):212-4. No abstract available.

17.

Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.

Weber R, Diener HC.

J Cell Mol Med. 2010 Oct;14(10):2371-80. doi: 10.1111/j.1582-4934.2010.01162.x. Review.

18.

Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?

Aw D, Sharma JC.

Postgrad Med J. 2012 Jan;88(1035):34-7. doi: 10.1136/postgradmedj-2011-130100. Epub 2011 Nov 25. Review.

PMID:
22121248
19.

Antiplatelets and stroke outcomes: state of the science.

Meyer D.

Crit Care Nurs Clin North Am. 2009 Dec;21(4):517-28. doi: 10.1016/j.ccell.2009.07.016. Review.

PMID:
19951767
20.

Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke.

Greer DM.

CNS Drugs. 2010 Dec;24(12):1027-40. doi: 10.2165/11539160-000000000-00000. Review.

PMID:
20932071
Items per page

Supplemental Content

Write to the Help Desk